Experts in the development of inhaled medicines, we are passionate about generating better outcomes for patients globally.
To develop innovative inhalation therapies that offer rapid, reliable, and non-invasive treatment options for underserved conditions.
To enhance the quality of life for tens of millions by providing effective and affordable solutions to every corner of the world.
Pulmonary delivery of medications plays a crucial role in treating conditions that benefit from a rapid onset of action, enhanced bioavailability, or a non-invasive route of administration.
Formulating drugs for delivery to the lungs requires the thoughtful selection of ingredients and components to optimise particle size distribution for deep lung deposition while ensuring safety and chemical stability.
Volatile active ingredients present even greater challenges for lung delivery. These molecules vaporise rapidly when released as an aerosol, leading to inconsistent dose delivery to the lower lungs.
Inhaled Solutions has developed a patent-pending technique for pressurised metered dose inhalers that enables the encapsulation of volatile molecules within droplets of respirable size.
Our approach delays release of the active by combining excipients of varying densities to hold the active in the centre of droplets while outer layers evaporate off.
This reduces the premature escape of the active dose into the atmosphere and minimises oropharyngeal deposition, which can cause local irritation or metabolism in the gastrointestinal tract.
Next-generation nicotine replacement therapy (NRT) for discreet and effective craving relief.
Non-opioid analgesics for the rapid relief of pain in emergency settings.
Improved shelf life stability and rapid-response treatment for angina.
Our platform enables the formulation of drugs that have traditionally been challenging to develop for pulmonary delivery.
Highly controlled particle size distribution delivers more dose to desirable regions of the lungs, improving efficacy and reducing side-effects.
Up to 200 doses in a low-cost and shelf-stable device means our products can be accessible to everyone, not just those in wealthy countries.
Inhaled Solutions' team and network of partners possess world-leading expertise in the development of nasal and inhalation drug-device combination products, and can support your development from idea through to commercial success.
Inhaler Supplies Pty Ltd
Level 3, 360 Kent St
Sydney NSW 2000
Australia